JP2010532364A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010532364A5 JP2010532364A5 JP2010514996A JP2010514996A JP2010532364A5 JP 2010532364 A5 JP2010532364 A5 JP 2010532364A5 JP 2010514996 A JP2010514996 A JP 2010514996A JP 2010514996 A JP2010514996 A JP 2010514996A JP 2010532364 A5 JP2010532364 A5 JP 2010532364A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrol
- pyrrolo
- imidazo
- dioxo
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 28
- 239000002246 antineoplastic agent Substances 0.000 claims 20
- 229940127089 cytotoxic agent Drugs 0.000 claims 20
- 229910052697 platinum Inorganic materials 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 239000012453 solvate Substances 0.000 claims 14
- -1 pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl Chemical group 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000000243 solution Substances 0.000 claims 6
- HRJWTAWVFDCTGO-UHFFFAOYSA-N LY-2090314 Chemical compound C1CN(C=23)C=C(C=4C(NC(=O)C=4C=4N5C=CC=CC5=NC=4)=O)C3=CC(F)=CC=2CN1C(=O)N1CCCCC1 HRJWTAWVFDCTGO-UHFFFAOYSA-N 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 4
- 229960004562 carboplatin Drugs 0.000 claims 4
- 229960004316 cisplatin Drugs 0.000 claims 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229960002949 fluorouracil Drugs 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 4
- 229960005079 pemetrexed Drugs 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- YPZARNMVEFFLNZ-UHFFFAOYSA-N 1,10-diazatricyclo[6.4.1.04,13]trideca-2,4(13),5,7,9,11-hexaene Chemical compound C1=CN=CC2=CC=CC3=C2N1C=C3 YPZARNMVEFFLNZ-UHFFFAOYSA-N 0.000 claims 2
- GUJAGMICFDYKNR-UHFFFAOYSA-N 1,4-benzodiazepine Chemical compound N1C=CN=CC2=CC=CC=C12 GUJAGMICFDYKNR-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 2
- 229960005420 etoposide Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94751207P | 2007-07-02 | 2007-07-02 | |
| US60/947,512 | 2007-07-02 | ||
| PCT/US2008/067614 WO2009006043A2 (en) | 2007-07-02 | 2008-06-20 | Potentiation of cancer chemotherapy by 7-(2,5-dihydro-4-imidazo [1,2-a]pyrine-3-yl-2,5-dioxo-ih-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro-2-(1-piperidinyl-carbonyd-pyrrolo[3,2,1-jk][1,4]benzodiazepine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014006560A Division JP2014114297A (ja) | 2007-07-02 | 2014-01-17 | ７−（２，５−ジヒドロ−４−イミダゾ［１，２−ａ］ピリジン−３−イル−２，５−ジオキソ−１Ｈ−ピロロ−３−イル）−９−フルオロ−１，２，３，４−テトラヒドロ−２−（１−ピペリジニル−カルボニル）ピロロ［３，２，１−ｊｋ］［１，４］ベンゾジアゼピンによる癌化学療法の相乗作用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010532364A JP2010532364A (ja) | 2010-10-07 |
| JP2010532364A5 true JP2010532364A5 (OSRAM) | 2011-08-04 |
| JP5551589B2 JP5551589B2 (ja) | 2014-07-16 |
Family
ID=39737054
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010514996A Expired - Fee Related JP5551589B2 (ja) | 2007-07-02 | 2008-06-20 | ７−（２，５−ジヒドロ−４−イミダゾ［１，２−ａ］ピリジン−３−イル−２，５−ジオキソ−１Ｈ−ピロロ−３−イル）−９−フルオロ−１，２，３，４−テトラヒドロ−２−（１−ピペリジニル−カルボニル）ピロロ［３，２，１−ｊｋ］［１，４］ベンゾジアゼピンによる癌化学療法の相乗作用 |
| JP2014006560A Pending JP2014114297A (ja) | 2007-07-02 | 2014-01-17 | ７−（２，５−ジヒドロ−４−イミダゾ［１，２−ａ］ピリジン−３−イル−２，５−ジオキソ−１Ｈ−ピロロ−３−イル）−９−フルオロ−１，２，３，４−テトラヒドロ−２−（１−ピペリジニル−カルボニル）ピロロ［３，２，１−ｊｋ］［１，４］ベンゾジアゼピンによる癌化学療法の相乗作用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014006560A Pending JP2014114297A (ja) | 2007-07-02 | 2014-01-17 | ７−（２，５−ジヒドロ−４−イミダゾ［１，２−ａ］ピリジン−３−イル−２，５−ジオキソ−１Ｈ−ピロロ−３−イル）−９−フルオロ−１，２，３，４−テトラヒドロ−２−（１−ピペリジニル−カルボニル）ピロロ［３，２，１−ｊｋ］［１，４］ベンゾジアゼピンによる癌化学療法の相乗作用 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8318713B2 (OSRAM) |
| EP (1) | EP2173348B1 (OSRAM) |
| JP (2) | JP5551589B2 (OSRAM) |
| KR (1) | KR101230085B1 (OSRAM) |
| CN (2) | CN101743005B (OSRAM) |
| AR (1) | AR067112A1 (OSRAM) |
| AU (1) | AU2008270732B2 (OSRAM) |
| BR (1) | BRPI0813789A2 (OSRAM) |
| CA (1) | CA2691587C (OSRAM) |
| CL (2) | CL2008001848A1 (OSRAM) |
| EA (2) | EA018447B1 (OSRAM) |
| ES (1) | ES2561202T3 (OSRAM) |
| IL (2) | IL202237A (OSRAM) |
| MA (1) | MA31677B1 (OSRAM) |
| MX (1) | MX2009013449A (OSRAM) |
| MY (1) | MY154472A (OSRAM) |
| NZ (1) | NZ581355A (OSRAM) |
| PE (1) | PE20090838A1 (OSRAM) |
| TW (1) | TWI428132B (OSRAM) |
| UA (1) | UA97400C2 (OSRAM) |
| WO (1) | WO2009006043A2 (OSRAM) |
| ZA (1) | ZA200908725B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI428132B (zh) * | 2007-07-02 | 2014-03-01 | Lilly Co Eli | 癌症化療效果之強化 |
| CA2758473C (en) * | 2009-04-14 | 2013-12-17 | Eli Lilly And Company | Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia |
| EP2747761A1 (en) * | 2011-09-22 | 2014-07-02 | Bind Therapeutics, Inc. | Methods of treating cancers with therapeutic nanoparticles |
| WO2014050779A1 (ja) * | 2012-09-25 | 2014-04-03 | 第一三共株式会社 | Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ |
| JP6364546B2 (ja) * | 2015-04-30 | 2018-07-25 | 大鵬薬品工業株式会社 | 抗腫瘍剤の副作用軽減剤 |
| US10213511B2 (en) * | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| US10016507B2 (en) * | 2016-03-02 | 2018-07-10 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III |
| SG10201910821XA (en) | 2016-12-30 | 2020-01-30 | Frequency Therapeutics Inc | 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
| WO2020163812A1 (en) | 2019-02-08 | 2020-08-13 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| AU2022285754A1 (en) * | 2021-06-03 | 2023-12-14 | University Of Cincinnati | Bzd-1 as a chemosensitizer of cancer |
| CN113956157B (zh) * | 2021-11-18 | 2024-05-03 | 西安都创医药科技有限公司 | 一种合成2-甲酰基-1-环丙烷甲酸乙酯的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8904161D0 (en) * | 1989-02-23 | 1989-04-05 | Hoffmann La Roche | Substituted pyrroles |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| EP1788086A1 (en) * | 1997-03-17 | 2007-05-23 | Human Genome Sciences, Inc. | Death Domain Containing Receptor 5 |
| US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| PT1483265E (pt) * | 2002-03-05 | 2007-01-31 | Lilly Co Eli | Derivados de purina como inibidores de quinase |
| MXPA05003058A (es) * | 2002-09-19 | 2005-05-27 | Schering Corp | Nuevas imidazopiridinas como inhibidores de cinasa dependientes de ciclina. |
| AU2005262925B2 (en) | 2004-07-09 | 2011-01-20 | Agency For Science, Technology And Research | Modulation of GSK-3beta and method of treating proliferative disorders |
| GB0418328D0 (en) | 2004-08-17 | 2004-09-22 | Imp College Innovations Ltd | Cancer methods and medicaments |
| KR20080026093A (ko) * | 2005-05-04 | 2008-03-24 | 유니버시티 오브 사우스 플로리다 | 암 환자의 치료 반응을 예측하는 방법 |
| TWI428132B (zh) * | 2007-07-02 | 2014-03-01 | Lilly Co Eli | 癌症化療效果之強化 |
-
2008
- 2008-06-18 TW TW097122720A patent/TWI428132B/zh not_active IP Right Cessation
- 2008-06-19 PE PE2008001054A patent/PE20090838A1/es not_active Application Discontinuation
- 2008-06-20 JP JP2010514996A patent/JP5551589B2/ja not_active Expired - Fee Related
- 2008-06-20 CN CN2008800231969A patent/CN101743005B/zh not_active Expired - Fee Related
- 2008-06-20 AR ARP080102668A patent/AR067112A1/es unknown
- 2008-06-20 CN CN2012101150238A patent/CN102772416A/zh active Pending
- 2008-06-20 US US12/664,664 patent/US8318713B2/en not_active Expired - Fee Related
- 2008-06-20 ES ES08771559.5T patent/ES2561202T3/es active Active
- 2008-06-20 CL CL2008001848A patent/CL2008001848A1/es unknown
- 2008-06-20 EA EA201070085A patent/EA018447B1/ru not_active IP Right Cessation
- 2008-06-20 WO PCT/US2008/067614 patent/WO2009006043A2/en not_active Ceased
- 2008-06-20 NZ NZ581355A patent/NZ581355A/en not_active IP Right Cessation
- 2008-06-20 MY MYPI20095640A patent/MY154472A/en unknown
- 2008-06-20 EA EA201201155A patent/EA023697B1/ru not_active IP Right Cessation
- 2008-06-20 UA UAA200913938A patent/UA97400C2/uk unknown
- 2008-06-20 AU AU2008270732A patent/AU2008270732B2/en not_active Ceased
- 2008-06-20 EP EP08771559.5A patent/EP2173348B1/en active Active
- 2008-06-20 BR BRPI0813789-7A2A patent/BRPI0813789A2/pt not_active IP Right Cessation
- 2008-06-20 MX MX2009013449A patent/MX2009013449A/es active IP Right Grant
- 2008-06-20 CA CA2691587A patent/CA2691587C/en not_active Expired - Fee Related
- 2008-06-20 KR KR1020097027543A patent/KR101230085B1/ko not_active Expired - Fee Related
-
2009
- 2009-11-19 IL IL202237A patent/IL202237A/en not_active IP Right Cessation
- 2009-12-08 ZA ZA2009/08725A patent/ZA200908725B/en unknown
-
2010
- 2010-01-27 MA MA32562A patent/MA31677B1/fr unknown
-
2011
- 2011-12-02 CL CL2011003046A patent/CL2011003046A1/es unknown
-
2012
- 2012-03-01 IL IL218443A patent/IL218443A0/en unknown
- 2012-10-18 US US13/654,884 patent/US8648063B2/en not_active Expired - Fee Related
-
2014
- 2014-01-17 JP JP2014006560A patent/JP2014114297A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010532364A5 (OSRAM) | ||
| AU2008270732B2 (en) | Potentiation of cancer chemotherapy by 7-(2,5-dihydro-4-imidazo[1,2-a]pyridine-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)-pyrrolo[3,2,1-jk][1,4]benzodiazepine | |
| JP2012524089A5 (OSRAM) | ||
| ES2608656T3 (es) | Inhibidores de quinasa de punto de control 1 para la potenciación de agentes que dañan el ADN | |
| IL196243A (en) | [4,2,1] Triazole [3,4– a Pyridine Derivatives | |
| JP2010180210A5 (OSRAM) | ||
| JP2015519330A5 (OSRAM) | ||
| JP2011503071A5 (ja) | ヨードニトロベンズアミド化合物と抗腫瘍剤の組み合わせによる卵巣がんの治療 | |
| ES2705529T3 (es) | Tratamiento combinatorio del cáncer | |
| IL215911A (en) | 7-aryl-1,2,4-triazolo [3,4- a] derivatives, pharmaceutical preparations containing them and methods of preparation and uses thereof | |
| EA201171243A1 (ru) | Производное бензодиазепина для лечения гематопоэтических новообразований и лейкоза | |
| RU2009127351A (ru) | Комбинации антифолатного агента в лечении рака | |
| WO2010017325A3 (en) | Thermally-activatable liposome compositions and methods for imaging, diagnosis and therapy | |
| IL198180A (en) | Salt p- toluene 5-amino-3-sulfonic acid (2'-0-acetyl-3'-deoxy-ß-d-riboforanosyl) -3h-thiazole [5,4- d] pyrimidine-2-on crystalline form , A pharmaceutical product containing it, its use in the preparation of a drug and methods for its manufacture | |
| JP2007277240A5 (OSRAM) | ||
| WO2007071965A3 (en) | Antibacterial pyrrolopyridines, pyrrolopyrimidines, and pyrroloazepines | |
| JP2012508239A5 (OSRAM) | ||
| JP2008501007A (ja) | 異常な細胞増殖を治療するための方法 | |
| TH114619A (th) | การเสริมผลของเคมีบำบัดมะเร็ง | |
| HK1141236B (en) | Potentiation of cancer chemotherapy | |
| MXPA06008857A (en) | COMBINATION OF (a) A DNA TOPOISOMERASE INHIBITOR AND (b) AN IAP INHIBITOR |